493 related articles for article (PubMed ID: 25938794)
1. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
2. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
[TBL] [Abstract][Full Text] [Related]
3. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
4. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
5. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Wonder M; Dunlop S
Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
[TBL] [Abstract][Full Text] [Related]
7. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
8. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
Sinha Y; Brien JA; Craig JC
J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
[TBL] [Abstract][Full Text] [Related]
9. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Wonder MJ; Neville AM; Parsons R
Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
[TBL] [Abstract][Full Text] [Related]
10. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
11. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
12. Delays in access to affordable medicines: putting policy into perspective.
Pearce A; van Gool K; Haywood P; Haas M
Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
Lybrand S; Wonder M
Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
[TBL] [Abstract][Full Text] [Related]
14. What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?
Rawson N
J Popul Ther Clin Pharmacol; 2017 Dec; 24(3):90-98. PubMed ID: 29432671
[TBL] [Abstract][Full Text] [Related]
15. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
16. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
17. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
18. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
19. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
20. Policies and availability of orphan medicines in outpatient care in 24 European countries.
Sarnola K; Ahonen R; Martikainen JE; Timonen J
Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
